$2.40 Million in Sales Expected for Advaxis, Inc. (ADXS) This Quarter

Brokerages expect that Advaxis, Inc. (NASDAQ:ADXS) will report sales of $2.40 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Advaxis’ earnings, with the highest sales estimate coming in at $3.00 million and the lowest estimate coming in at $1.79 million. Advaxis reported sales of $3.05 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 21.3%. The business is scheduled to issue its next quarterly earnings report on Monday, September 10th.

On average, analysts expect that Advaxis will report full year sales of $9.20 million for the current fiscal year, with estimates ranging from $7.39 million to $11.00 million. For the next fiscal year, analysts anticipate that the firm will post sales of $9.38 million per share, with estimates ranging from $7.16 million to $11.60 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Advaxis.

Advaxis (NASDAQ:ADXS) last issued its earnings results on Monday, March 12th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.06. Advaxis had a negative net margin of 1,041.73% and a negative return on equity of 168.35%. The firm had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $3.03 million.

A number of research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Advaxis in a report on Tuesday, April 17th. Cantor Fitzgerald cut their price objective on shares of Advaxis from $19.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, March 13th. ValuEngine raised shares of Advaxis from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, Jefferies Financial Group cut shares of Advaxis from a “buy” rating to a “hold” rating and cut their price objective for the company from $9.00 to $2.00 in a report on Wednesday. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $3.33.

Advaxis traded up $0.01, reaching $1.69, on Monday, according to Marketbeat. The stock had a trading volume of 541,641 shares, compared to its average volume of 870,392. Advaxis has a 12-month low of $1.51 and a 12-month high of $7.45. The stock has a market capitalization of $97.35 million, a price-to-earnings ratio of -0.73 and a beta of 1.40.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ADXS. Wells Fargo & Company MN increased its holdings in Advaxis by 39.9% in the fourth quarter. Wells Fargo & Company MN now owns 66,206 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 18,892 shares in the last quarter. DAFNA Capital Management LLC increased its holdings in Advaxis by 182.2% in the first quarter. DAFNA Capital Management LLC now owns 697,000 shares of the biotechnology company’s stock valued at $1,178,000 after buying an additional 450,000 shares in the last quarter. Bank of Montreal Can increased its holdings in Advaxis by 16,465.9% in the fourth quarter. Bank of Montreal Can now owns 433,198 shares of the biotechnology company’s stock valued at $1,230,000 after buying an additional 430,583 shares in the last quarter. Deutsche Bank AG increased its holdings in Advaxis by 1,200.1% in the fourth quarter. Deutsche Bank AG now owns 467,324 shares of the biotechnology company’s stock valued at $1,326,000 after buying an additional 431,379 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Advaxis during the fourth quarter worth about $1,398,000. 32.94% of the stock is owned by institutional investors.

About Advaxis

Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.

Get a free copy of the Zacks research report on Advaxis (ADXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply